Evaluation of Circulating Immune Response After Histosonics in Colorectal Cancer (ECHO-CRC)

Overview

This is a single-center, non-randomized, open-label, single-arm pilot study investigating the systemic immune response to histotripsy in patients with colorectal cancer with liver metastasis. Histotripsy is an FDA-approved, non-invasive therapeutic modality for the treatment of liver tumors, including both primary and metastatic lesions. In this study, investigators aim to evaluate the kinetics of peripheral T-cell response following histotripsy of colorectal cancer liver metastases (CRCLM). Given the well-documented immune-tolerant tumor microenvironment of liver metastases and their role in systemic resistance to checkpoint inhibitors, investigators hypothesize that histotripsy-induced tumor disruption will lead to measurable alterations in peripheral T-cell clonal expansion and exhaustion markers. Investigators will assess these changes via serial blood draws before and after histotripsy, with the goal of characterizing the systemic immune impact of local tumor ablation. Findings from this study may inform future combination strategies integrating histotripsy with immunotherapy to enhance treatment response in microsatellite-stable CRC

Detailed description

This is a single-center, non-randomized, open-label, single-arm pilot study investigating the systemic immune response to histotripsy in patients with colorectal cancer with liver metastasis. Histotripsy is an FDA-approved, non-invasive therapeutic modality for the treatment of liver tumors, including both primary and metastatic lesions. In this study, investigators aim to evaluate the kinetics of peripheral T-cell response following histotripsy of colorectal cancer liver metastases (CRCLM). Given the well-documented immune-tolerant tumor microenvironment of liver metastases and their role in systemic resistance to checkpoint inhibitors, investigators hypothesize that histotripsy-induced tumor disruption will lead to measurable alterations in peripheral T-cell clonal expansion and exhaustion markers. Investigators will assess these changes via serial blood draws before and after histotripsy, with the goal of characterizing the systemic immune impact of local tumor ablation. Findings from this study may inform future combination strategies integrating histotripsy with immunotherapy to enhance treatment response in microsatellite-stable CRC

Interventions

• Procedure Histotripsy
  This is a single-center, non-randomized, open-label, single-arm pilot study investigating the systemic immune response to histotripsy in patients with colorectal cancer with liver metastasis. Histotripsy is an FDA-approved, non-invasive therapeutic modality for the treatment of liver tumors, including both primary and metastatic lesions. In this study, we aim to evaluate the kinetics of peripheral T-cell response following histotripsy of colorectal cancer liver metastases (CRCLM). Given the wel

Primary outcome measures

• Measure of System Immune Modulation via T-cells [Time frame: 2 years]

Secondary outcome measures (1)

• Assess the Kinetics of Peripheral Immune Cell Response via T-cells [Time frame: 2 years]

Eligibility criteria

Inclusion criteria

• Gender: Both male and female patients will be eligible for enrollment.

• Age at least 18 years.
• Histologic (biopsy-proven) confirmation of metastatic microsatellite stable colorectal cancer with at least one radiographically evident hepatic metastasis.
• Planned treatment with standard-of-care histotripsy.
• Radiographic confirmation of hepatic metastases with computed tomography (CT) or magnetic resonance imaging (MRI), with CT preferred. Imaging must be performed within 60 days of the date of consent.
• Adequate organ and marrow function as defined below:

• Absolute neutrophil count: ≥ 1,000/mcL
• Platelets: ≥ 100,000/mcL
• Total bilirubin ≤ 3x the upper limit of normal (ULN). This may be up to 5x ULN if Gilbert's syndrome is documented.
• AST and ALT ≤ 8x institutional ULN.
• Serum creatinine ≤ 2x ULN unless on dialysis.
• Eastern Cooperative Oncology Group (ECOG) performance status 0 to 3.
• Estimated life expectancy of at least 90 days as determined by the treating physician.
• Demographic group: There are no restrictions based on race or ethnicity. Efforts will be made to ensure a representative patient population reflecting the diversity of individuals affected by CRCLM.
• Ability to understand and willingness to sign a written informed consent document.

Exclusion criteria

• Major surgical procedure or significant traumatic injury within 14 days prior to histotripsy.

• Therapy with an investigational drug within 14 days prior to histotripsy.
• Clinically significant cardiovascular or cerebrovascular disease, including:

• Myocardial infarction within 3 months prior to enrollment.
• Unstable angina.
• Congestive heart failure (New York Heart Association Classification Class > II).

v. 3.0 22July2025 9

• Serious cardiac arrhythmia (controlled atrial fibrillation or definitively treated arrhythmias via ablation are not considered exclusion criteria).
• Cerebrovascular stroke with deficit within 3 months prior to enrollment.
• Active infection requiring systemic therapy within 14 days prior to histotripsy, unless deemed to be a chronic disease state by the study PI.
• Active pregnancy.
• Patients with active infections, autoimmune diseases requiring systemic immunosuppression, or other uncontrolled comorbidities that could interfere with study participation will be excluded.
• Severe cancer-associated cachexia that may interfere with systemic immune response, as assessed by the treating physician.
• Any ongoing medical illness or injury that would significantly impact tolerability of therapy, including but not limited to:

• Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture.
• Clinical signs or symptoms of gastrointestinal obstruction or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding.
• Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates histotripsy, may affect the interpretation of study results, or may render the patient at high risk for treatment complications.
• Anyone that is unable to consent due to cognitive, psychological or other reasons that impact their capacity.
• Deemed to be inappropriate for enrollment by the study PI.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

United States · 1 center

• Zuckerberg Cancer Center — New Hyde Park

Identifiers

NCT: NCT07361107 · 25-0632

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗